Using semaglutide to treat advanced lung disease
Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study
This study is testing if a diabetes and weight loss medication called semaglutide can be safely used by adults with advanced lung diseases to see if it helps them manage their weight better.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 8 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Trial ID | NCT05746039 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the feasibility and tolerability of semaglutide, a medication approved for diabetes and obesity, in patients with advanced lung diseases such as interstitial lung disease, COPD, and pulmonary hypertension. The study involves a small group of adults who will undergo pulmonary function tests, physical assessments, and body composition evaluations before and after a 12-week treatment period with semaglutide. Participants will also be monitored for any adverse effects during the therapy. The goal is to determine if patients can tolerate the medication and if it can help them achieve a target weight.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a BMI over 30 and a diagnosis of advanced lung disease requiring supplemental oxygen.
Not a fit: Patients with diabetes, recent weight loss, or certain gastrointestinal issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could improve the management of weight and physical function in patients with advanced lung disease.
How similar studies have performed: While the use of semaglutide in this specific population is novel, similar studies have shown promising results in other contexts.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension * Age \> 18 * BMI \> 30 kg/m2 * Requires supplemental oxygen on exertion * Stable treatment regimen X 90 days * Use of disease-modifying therapy Exclusion Criteria: * Diabetes * Pregnant or Breastfeeding * Recent weight loss * Recent or chronic GI complaints * History of gastroparesis * History of scleroderma * Hospitalized at time of evaluation * Use of weight loss medication in last 90 days * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2) * Uncontrolled thyroid disease * History of acute/chronic pancreatitis * Prior suicide attempt * Suicidal ideation in last 90 days * Presence of a pacemaker or defibrillator
Where this trial is running
Philadelphia, Pennsylvania
- University of Pennsylvania Perelman School of Medicine — Philadelphia, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Michaela R Anderson, MD — University of Pennsylvania
- Study coordinator: Michaela R Anderson, MD
- Email: michaela.anderson@pennmedicine.upenn.edu
- Phone: 215-662-3202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.